

FEIBA® (anti-inhibitor coagulant complex)

When requesting Feiba, the individual requiring treatment must be diagnosed with one of the following FDA-approved indication or approved compendial use and meet the specific coverage guidelines and applicable safety criteria for the covered indication.

FDA-Approved Indication

Feiba is an anti-inhibitor coagulant complex indicated for use in hemophilia A and B patients with inhibitors for:

- Control and prevention of bleeding episodes
- Perioperative management
- Routine prophylaxis to prevent or reduce the frequency of bleeding episodes

Approved Off-label Compendial Use

- Treatment of bleeding episodes in individuals with acquired hemophilia A

Coverage Guidelines

Hemophilia A or B with inhibitors

- The request is for treatment or prevention of bleeding episodes or perioperative management of bleeding

Acquired hemophilia A

- The request is for treatment of bleeding episodes

Approval duration (initial): 3 months

Approval duration (renewal): 12 months

Dosing Recommendations

For intravenous use only

Type of Bleeding	Dose (unit/kg)	Frequency/Duration
Control and prevention of bleeding	50-100	Determined by the type of bleeding episode
Perioperative management	50-100	Determined by the type of surgical intervention
Routine prophylaxis	85	Every other day

References

1. Feiba prescribing information. Lexington, MA; Baxalta US Inc. March 2024.
2. Anti-inhibitor coagulant complex (FEIBA®). Lexi-Drugs. Lexicomp. Wolters Kluwer Health, Inc. Riverwoods, IL. [Updated; July 7, 2024; Accessed August 2, 2024].
3. National Hemophilia Foundation for all bleeding disorders. MASAC Recommendations Concerning Products Licensed for the Treatment of Hemophilia and Selected Disorders of the Coagulation System. MASAC Document #284. Revised April 2024.
4. National Hemophilia Foundation for all bleeding disorders. MASAC Recommendation Concerning Prophylaxis for Hemophilia A and B with and without Inhibitors. MASAC Document #267. Revised April 2022.
5. National Hemophilia Foundation for all bleeding disorders. MASAC Recommendation on Administration of Inhibitor Bypassing Agents in the Home for Patients with Hemophilia and Inhibitors. MASAC Document #274. Revised September 2022.

FEIBA® (anti-inhibitor coagulant complex)